NFL Biosciences is changing its governance. In its meeting of February 27, 2023, the Board of Directors took note of Joël Besse’s wish to free himself from his position, and he is thus replaced by Ignacio Faus, Chairman and Chief Executive Officer. With this appointment, the company can continue to make progress towards its goals in researching and developing innovative botanical medicines for the treatment of addictions and addictions.
Holder of a doctorate in Biochemistry from Indiana University in the United States, as well as an MBA in Entrepreneurship and Finance from the Kellogg School of Management at Northwestern University, Ignacio Faus has a solid experience in large and medium-sized pharmaceutical companies as well as in private and listed biotechnology companies. The latter arrived at NFL Biosciences in 2019 as an investor, then he joined the management team in early 2021. In addition, he has been a director of several private and listed biotechnology companies, as well as Private Equity funds in Europe and the United States. UNITED STATES.
“I am very honored to take the presidency of NFL Biosciences and would like to sincerely thank Joël Besse for his operational and financial involvement since 2018. After his support during the IPO, the company now has a secure financial position for the 18 months to come, following the capital increase and the Bpifrance financing concluded recently”said Ignacio Faus, CEO of NFL Biosciences.
